Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Relapsed/Refractory Aplastic Anemia
NCT06791824Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in aplastic anemia, sponsored by Keymed Biosciences. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
cm313
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06791824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791824.